Curium is the world's largest nuclear medicine company, with over €1 billion in revenues. We develop, manufacture and supply radiopharmaceutical products — SPECT, PET and therapeutic — to more than 14 million patients every year, through a network of manufacturing facilities across Europe and the United States.
We operate in a high-growth niche: beyond our established diagnostic imaging franchise, we are rapidly expanding into oncology therapeutics, building new manufacturing capacity and growing our commercial footprint globally. Curium is PE-backed (LBO) and known for a fast-paced, performance-driven culture.
This is a newly created position within Curium's five-person Corporate Treasury team (Incl. the candidate), based at our Paris headquarters. You will join a team that owns all central treasury activities: senior debt management, FX and interest rate hedging, TMS administration, treasury reporting and cash flow forecasting, liquidity management, surplus cash investment, off-balance sheet commitments and banking relationships.
Reporting to the Group Treasurer, you will be given real operational ownership from day one — processing payments, managing bank accounts and contributing to continuous improvement of our treasury tools and processes across an international, multi-currency Group.
Systems you'll work with: Diapason TMS, Neofi, Trustpair (anti-fraud), FX-All, Fairways Guarantee, Jira, and multiple bank web portals.
Why Curium?
Curium is the global leader in nuclear medicine, providing life-changing diagnostics and treatment to patients all over the world.
We develop, manufacture and distribute world-class radiopharmaceutical products with a renewed focus on cancer, exploring untapped potential for new innovation.
We build on remarkable foundations and a legacy of providing reliable and consistent nuclear solutions to tens of thousands of patients every day. Our proven heritage combined with a pioneering approach are the hallmarks from which we provide life-changing diagnostics and therapeutics. Our people are the root of the incredible impact they have.
As part of our 2030 vision to become an oncology-focused nuclear medicine leader – both in diagnostics and therapy – we will expand our reach further into Japan and China, continuing to roll out our superior products to a global market. The impact of these investments on patients will be life changing.
Our cancer focus is currently in Neuroendocrine Tumors (NETs) and prostate cancer PSMA. We are also working on leveraging the power of AI to improve image quality and accuracy; to identify patterns to help diagnose pathologies and of course to better support physicians.
Our Promise
We strive to make the impossible possible and to be an organization that will change the face of medicine. Our diverse group of industry experts is unified under one strong and singular focus – to develop, manufacture and supply revolutionary diagnostic and therapeutic radiopharmaceuticals to our customers around the globe with unrivaled reliability and superior service.
